Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,122 stopped studies mapped to Non-Small Cell Carcinoma and descendants · 90% state a reason
Over the 1,122 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04984811 | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally… | Phase 2 | terminated | Aug 2, 2021 | NeoImmuneTech | sponsor decision (not for safety) | Safety / toxicity |
| NCT06267001 | A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in…(SKYSCRAPER-15) | Phase 3 | terminated | Feb 20, 2024 | Hoffmann-La Roche | Decision to terminate study was driven by results from preceding tiragolumab study… | Safety / toxicity |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In… | Phase 2 | terminated | Jun 7, 2021 | Regeneron Pharmaceuticals | Sponsor Decision related to study drug supply | Drug supply |
| NCT04748419 | Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting… | Phase 1 / Phase 2 | terminated | Feb 10, 2021 | University of Nebraska | Poor accrual | Enrollment / accrual |
| NCT04189614 | An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With… | Phase 1 | terminated | Dec 6, 2019 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT05062980 | Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously…(Acclaim-2) | Phase 1 | terminated | Sep 30, 2021 | Genprex, Inc. | Enrollment was slow, due to competition with the many other clinical trials for the same patient… | Enrollment / accrual |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Dec 15, 2023 | Genmab | Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk… | Other (stated, no rule matched) |
| NCT06558799 | LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With…(LUNAR-4) | Phase 2 | terminated | Aug 19, 2024 | NovoCure GmbH | EF-50/LUNAR-4 was terminated because available real-world data are expected to enable Novocure to… | Safety / toxicity |
| NCT03237377 | Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | Phase 2 | terminated | Aug 2, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | low accrual | Enrollment / accrual |
| NCT03520686 | Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | Phase 3 | terminated | May 11, 2018 | ImmunityBio, Inc. | There are no longer active subjects on QUILT-2.023. Data will be entered into clinicaltrials.gov… | Other (stated, no rule matched) |
| NCT06685718 | A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor… | Phase 1 | terminated | Nov 12, 2024 | BeOne Medicines | Evaluation on business strategy, not involving safety issue. | Safety / toxicity |
| NCT06704724 | A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other… | Phase 1 | terminated | Nov 26, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT04588246 | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to… | Phase 3 | terminated | Oct 19, 2020 | NRG Oncology | Inadequate accrual rate | Enrollment / accrual |
| NCT03645928 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Phase 2 | terminated | Aug 24, 2018 | Iovance Biotherapeutics, Inc. | After reviewing the available safety and efficacy data to date, Iovance concluded that the study… | Safety / toxicity |
| NCT03337698 | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With…(Morpheus Lung) | Phase 1 / Phase 2 | terminated | Nov 9, 2017 | Hoffmann-La Roche | Study was closed early as the sponsor decided not to continue development of certain treatment… | Sponsor / business decision |
| NCT04025515 | Molecular Profiling Project | — | suspended | Jul 19, 2019 | National Cancer Centre, Singapore | Discussion under way on how to continue/restart the study in view of slow recruitment rate. | Enrollment / accrual |
| NCT04746924 | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With… | Phase 3 | terminated | Feb 10, 2021 | BeiGene | This decision was conducted by the sponsor based on lack of efficacy and not driven by safety… | Safety / toxicity |
| NCT04878952 | Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve… | N/A | terminated | May 10, 2021 | NRG Oncology | will not be able to meet study accrual objectives. | Enrollment / accrual |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced… | Phase 1 | terminated | Mar 11, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT06653023 | Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer(Wondercel-UWD3) | Early Phase 1 | suspended | Oct 22, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT04786093 | Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC | Phase 2 | terminated | Mar 8, 2021 | University of Texas Southwestern Medical Center | Sponsor decision to halt funding. | Funding |
| NCT05812274 | Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients | N/A | terminated | Apr 13, 2023 | Columbia University | Funding was withdrawn | Funding |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2023 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT06192004 | Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and…(LOOP) | — | terminated | Jan 5, 2024 | AstraZeneca | Observed event rate was below the rate required to meet study objectives. | Other (stated, no rule matched) |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced… | Phase 1 / Phase 2 | terminated | May 26, 2021 | M.D. Anderson Cancer Center | PI requested. | Other (stated, no rule matched) |
| NCT06235242 | GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With… | N/A | terminated | Jan 31, 2024 | Grit Biotechnology | The study was terminated from a business perspective. | Sponsor / business decision |
| NCT06513663 | Exercise as Maintenance Therapy in Advanced Lung Cancer | N/A | terminated | Jul 22, 2024 | Indiana University | trial stopped due to low accrual | Enrollment / accrual |
| NCT03737994 | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for… | Phase 2 | terminated | Nov 13, 2018 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT04266730 | Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With…(PANDA-VAC) | Phase 1 | suspended | Feb 12, 2020 | UNC Lineberger Comprehensive Cancer Center | Not stated | Other (stated, no rule matched) |
| NCT06491225 | Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients… | Phase 1 | terminated | Jul 9, 2024 | Grit Biotechnology | The study was terminated from a business perspective. | Sponsor / business decision |
| NCT06974734 | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or… | Phase 1 | terminated | May 16, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT02257619 | Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung… | Phase 2 | terminated | Oct 6, 2014 | Incyte Corporation | Sponsor decision to not initiate part 2 due to slow enrollment and competing trials. | Enrollment / accrual |
| NCT02298153 | A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously… | Phase 1 | terminated | Nov 21, 2014 | Incyte Corporation | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | Phase 1 | terminated | May 17, 2023 | Aurigene Discovery Technologies Limited | Patient recruitment problems | Enrollment / accrual |
| NCT05397093 | ITIL-306 in Advanced Solid Tumors | Phase 1 | terminated | May 31, 2022 | Instil Bio | The study was terminated early due to discontinuation of development of the investigational program | Other (stated, no rule matched) |
| NCT00280189 | Study of Outcomes of Radiofrequency Ablation of Lung Tumors | — | suspended | Jan 20, 2006 | University of Pittsburgh | not stated | Not stated |
| NCT02764086 | INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll… | Phase 1 / Phase 2 | terminated | May 6, 2016 | Cancer Trials Ireland | Accrual lower than anticipated and not expected to improve | Enrollment / accrual |
| NCT06130254 | Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the… | Phase 1 | terminated | Nov 14, 2023 | M.D. Anderson Cancer Center | Sponsor discontinued the trial | Other (stated, no rule matched) |
| NCT04892017 | Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors | Phase 1 | terminated | May 19, 2021 | Deciphera Pharmaceuticals, LLC | Trial terminated due to business decision, not based on any safety or efficacy concerns. | Safety / toxicity |
| NCT06434103 | Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without… | Phase 1 / Phase 2 | withdrawn | May 30, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Sponsor's Strategy Adjustment | Sponsor / business decision |
| NCT02679963 | Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced…(PIPSeN) | Phase 2 | terminated | Feb 11, 2016 | Gustave Roussy, Cancer Campus, Grand Paris | study design, change of standard of care, enrollment difficulties | Enrollment / accrual |
| NCT04908111 | A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 | Phase 1 / Phase 2 | suspended | Jun 1, 2021 | Cancer Research UK | Sponsor has decided to permanently close recruitment | Enrollment / accrual |
| NCT03348748 | Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage… | Early Phase 1 | terminated | Nov 21, 2017 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT05765734 | A Study of TAS3351 in NSCLC Patients With EGFRmt(TAS3351) | Phase 1 | terminated | Mar 13, 2023 | Taiho Oncology, Inc. | Sponsor's decision, not based on safety concerns | Safety / toxicity |
| NCT06186076 | A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in… | Phase 1 / Phase 2 | terminated | Dec 29, 2023 | Therapex Co., Ltd | Sponsor's decision | Sponsor / business decision |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT04432207 | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung… | Phase 1 | terminated | Jun 16, 2020 | Imugene Limited | Portfolio prioritization | Sponsor / business decision |
| NCT04911166 | Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small… | Phase 1 | terminated | Jun 2, 2021 | The Methodist Hospital Research Institute | Poor accrual | Enrollment / accrual |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People… | Phase 1 | terminated | Aug 30, 2024 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | Phase 1 / Phase 2 | terminated | Mar 9, 2021 | M.D. Anderson Cancer Center | Insufficient accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jun 11, 2026source: clinicaltrials